In a following work [46], to overcome the limitations of therapies currently used in clinics to treat HER2-positive breast cancer, the same research group explored the potential theranostic use of fluorescent SiNP-TZ directly labeled with 99mTc on the histidine residues of Hc-TZ and loaded with the anticancer drug doxorubicin (Dox). The gene discussed is ERBB2; the disease is breast carcinoma.